ReviewFrontiers in immunology2020
Immunoregulatory Roles of Extracellular Vesicles and Associated Therapeutic Applications in Lung Cancer.
Review in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- A systematic review of extracellular vesicles as non-invasive biomarkers in glioma diagnosis, prognosis, and treatment response monitoring.Molecular biology reports · 2021Pooled it
- Extracellular Vesicles in Cancer: Biomarkers, Mechanisms, and Emerging Diagnostic Technologies.Advanced healthcare materials · 2026Review
- Immune Regulation and the Role of Extracellular Vesicles in Non-Small Cell Lung Cancer: Biological Mechanisms and Therapeutic Perspectives.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Application of dendritic cell extracellular vesicles as a valid nanoparticle platform for cancer therapies: a narrative review.Stem cell research & therapy · 2026Review
- Prognostic model of immune -related immune models of ANLN single gene based on TCGA lung adenocarcinoma database.Discover oncology · 2026Article
- Systemic toxicity and immunotoxicity studies of glucose oxidase-loaded extracellular vesicles derived from lung cancer cells.Frontiers in immunology · 2026Article
- Liquid biopsy biomarkers for cancer detection, treatment monitoring, and clinical outcome prediction.Frontiers in cell and developmental biology · 2026Review
- Strategies for Small Extracellular Vesicle-Based Cancer Immunotherapy.Research (Washington, D.C.) · 2024Review
- Review
- Engineered Microparticles for Treatment of Murine Brain Metastasis by Reprograming Tumor Microenvironment and Inhibiting MAPK Pathway.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- Review
- Apoptotic tumor cell-derived microparticles loading Napabucasin inhibit CSCs and synergistic immune therapy.Journal of nanobiotechnology · 2023Article
- Review
- Secretions from hypochlorous acid-treated tumor cells delivered in a melittin hydrogel potentiate cancer immunotherapy.Bioactive materials · 2022Article
- In Situ Deployment of Engineered Extracellular Vesicles into the Tumor Niche via Myeloid-Derived Suppressor Cells.Advanced healthcare materials · 2022Article
- Extracellular Vesicles and Interleukins: Novel Frontiers in Diagnostic and Therapeutic for Cancer.Frontiers in immunology · 2022Review
- Synergies of Extracellular Vesicles and Microchimerism in Promoting Immunotolerance During Pregnancy.Frontiers in immunology · 2022Review
- Commensal and Pathogenic Bacterial-Derived Extracellular Vesicles in Host-Bacterial and Interbacterial Dialogues: Two Sides of the Same Coin.Journal of immunology research · 2022Review
- Current status of and progress in the treatment of malignant pleural effusion of lung cancer.Frontiers in oncology · 2022Review
- Tumor-derived extracellular vesicles as messengers of natural products in cancer treatment.Theranostics · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer represents a fatal condition that has the highest morbidity and mortality among malignancies. The currently available treatments fall short of improving the survival and quality of life of late-stage lung cancer patients. Extracellular vesicles (EVs) secreted by tumors or immune cells transport proteins, lipids, and nucleic acids to other cells, thereby mediating immune regulation in the tumor microenvironment. The cargo carried by EVs vary by cellular state or extracellular milieu. So far, multiple studies have suggested that EVs from lung tumor cells (TEVs) or immune cells promote tumor progression mainly through suppressing antitumor immunity. However, modified or engineered EVs can be used as vaccines to elicit antitumor immunity. In addition, blocking the function of immunosuppressive EVs and using EVs carrying immunogenic medicine or EVs from certain immune cells also shows great potential in lung cancer treatment. To provide information for future studies on the role of EVs in lung cancer immunity, this review focus on the immunoregulatory role of EVs and associated treatment applications in lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.